Clinical Trials Logo
  1. Home
  2. 22q11.2 Deletion Syndrome
  3. NCT04639388

Understanding of Psychotic Disorders in Children With 22q11.2DS — PremiCeS22  

22q11.2 Deletion Syndrome Clinical Trial

Official title:
Characterize the Behavioral Prodromes of Psychotic Disorders in Children With 22q11.2DS Aged From 4 to 13 Years Old

Clinical Trial Summary

The study PremiCeS22 will investigate the prodromal signals at the onset of psychotic disorders of children with 22q11.2 deletion syndrome

Clinical Trial Description

22q11.2DS is one of the most common microdeletion syndromes (1 / 2000-1 / 4000 births) and one of the most robust genetic risk factors for schizophrenia (1 to 2% of cases). Reciprocally, approximately 30% of patients with 22q11.2DS will develop psychotic symptoms in adolescence or early adulthood. It is now well established that children and adults with 22q11.2DS have lower social skills than developing youth. These social dysfunctions could be partly underpinned by alterations in social cognitive processes, and could also be linked to the emergence of psychotic signs or even schizophrenia. However, to our knowledge, no study has investigated the existence of behavioral prodromal signs during the onset of psychotic signs in children with 22q11.2DS. In addition, the origin of social cognitive processes remains to this day little explored. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04639388
Study type Interventional
Source Hôpital le Vinatier
Contact Caroline DEMILY, MD PH
Phone 0450915163
Email caroline.demily@ch-le-vinatier.fr
Status Recruiting
Phase N/A
Start date November 13, 2020
Completion date January 31, 2025
View Details
See also
  Status Clinical Trial Phase
Terminated NCT04639960 - Neuroprotective Effects of Risperdal on Brain and Cognition in 22q11 Deletion Syndrome N/A
Recruiting NCT04373226 - Arithmetic Abilities in Children With 22q11.2DS N/A
Completed NCT01781923 - Cognitive Remediation in 22q11DS N/A
Terminated NCT03284060 - Social Cognition Training and Cognitive Remediation N/A
Completed NCT02895906 - Safety and Efficacy Study of NFC-1 in Subjects Aged 12-17 Years With 22q11.2DS & Associated Neuropsychiatric Conditions Phase 1
Completed NCT00916955 - Genetic Modifiers for 22q11.2 Syndrome
Recruiting NCT05924347 - Early Scoliotic Changes in Children at Increased Risk for Scoliosis Development
Recruiting NCT00556530 - Examining Genetic Factors That Affect the Severity of 22q11.2 Deletion Syndrome
Completed NCT02460328 - Resolution of Primary Immune Defect in 22q11.2 Deletion Syndrome N/A
Completed NCT04647500 - Effects of Methylphenidate on Brain and Cognition in 22q11 Deletion Syndrome N/A